September 14, 2011
IDIBELL Researchers Discover A Treatment Against An Aggressive Childhood Cancer
A molecule very similar to glucose kills tumor cells of alveolar rhabdomyosarcoma
A study made by IDIBELL researchers shows that glucose metabolism inhibition with 2-deoxyglucose (2-DG) induces cell death in a type of childhood sarcoma: alveolar rhabdomyosarcoma. The results have been published in the journal Cancer Research.
Rhabdomyosarcoma is the most common soft tissue tumor in children and adolescence, accounting for 4-5% of pediatric tumors. It occurs in two forms: embryonal rhabdomyosarcoma, the most frequent and less aggressive; and alveolar rhabdomyosarcoma, with worse prognosis.
The most widely used treatment for the latter type of sarcoma is surgery. Chemotherapy treatments are not effective and now the survival rate five years after diagnosis is 70%, which indicates that it is necessary to develop more effective treatments.
New therapeutic strategies
In this regard, in recent years it has increased interest in studying tumor metabolism as a potential therapeutic target. Several metabolic pathways have different functions in tumor cells and in healthy cells. Specifically, glycolysis (glucose oxidation for energy) is increased in some tumor cells. This makes them particularly sensitive to inhibitors of glycolysis such as 2-deoxyglucose.
The study, coordinated by the head of the group of Cell Death Regulation, Cristina MuÃ±oz-Pinedo, and the head of the group of Sarcomas, Oscar Martinez-Tirado shows that "in vitro" this molecule inhibits the metabolism of glucose needed by tumor cells, and causing their death.
According to researcher Cristina MuÃ±oz-Pinedo this molecule "slows the growth of tumor cells, causes their death and a percentage of them suffer a terminal differentiation, and present the appearance of healthy muscle cells."
This molecule is also very similar to that used in PET imaging techniques used to diagnose tumors with high metabolism of glucose. Because of this and the fact that there are ongoing clinical trials with other tumors, shows that, at high doses, this molecule has low toxicity and it would be relatively easy that it could be used in alveolar rhabdomyosarcoma treatment.
MuÃ±oz-Pinedo added that "knowing the mechanism that causes cell death of tumor cells, will be useful, in the future, to find more personalized treatments."
On the Net: